Lysosomes play an important role in protein degradation. Protein degradation drugs targeting the lysosomal degradation pathway can directly regulate disease-related protein levels in vivo. The lysosomal system and proteasome pathway are of two most significant degradation pathways in cells. PROTAC technology is known to provide a powerful tool for degrading many disease-causing ‘undruggable’ protein targets using the ubiquitin-proteasome system and has emerged as a promising approach for drug discovery. Lysosomal-based degradation technology may significantly broaden the target range that can be selectively degraded by exploiting another major degradation pathway in cells.
Lysosomes play a vital role in the degradation and recycling of extracellular material and in maintaining cell homeostasis. Lysosomes function in two ways, endocytosis for extracellular material and autophagy for intracellular material. Lysosomes contain various hydrolytic enzymes which can break down proteins, nucleic acids, polysaccharides, lipids, etc.
As a leading CRO in the pharmaceutical industry, BOC Sciences is committed to providing innovative small-molecule targeted drug development services to our global customers. With our experienced team of experts and extensive expertise, we are proud to have served our clients for over 10 years. In the field of targeted protein degradation, we possess extensive experience from successful projects and continue to broaden the boundaries of our technologies. The lysosomal system is one of the major pathways by which cells degrade extracellular and intracellular substances. We can provide drug discovery services using new strategies and technologies that target lysosomal degradation.
